Qixing Pharmaceutical Brand Ranking
If you want to improve the ranking of your company brand or wish to avoid appearing here, please contact trading@bossgoo.com.
Qixing Pharmaceutical

Qixing Pharmaceutical

Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd.
If you want to improve the ranking of your company brand or wish to avoid appearing here, please contact trading@bossgoo.com.
Brand Introduction

Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd. is affiliated to Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. and is a key subsidiary of Guangzhou Pharmaceutical Group. The company has a history of more than 140 years. It owns two major trademarks: "Baiyun Mountain" and "Qixing". The company has a product structure that mainly cardiovascular drugs and pediatric drugs as the auxiliary products. It has six dosage forms: pills, tablets, capsules, granules, powders, and mixtures, and its products are sold at home and abroad markets. Among them, Huatuo Rezai Pills are included in the National Medical Insurance Class A catalog and the National Basic Drug Catalog. They are also the product with a large export volume of a single variety of Chinese patent medicines in my country.

The company follows the business philosophy of "Guangyao Qixing, Pharmaceuticals seeking excellence", adheres to the corporate spirit of "unity, pioneering, realistic, efficient, moral integrity, trustworthiness, innovation, and harmony", and shines in the history of the development of traditional Chinese medicine.

The company has been constantly exploring the internationalization of traditional Chinese medicine for many years, creating the Huatuo Remade Pill Model of "making the world in line with traditional Chinese medicine", providing a reference for the internationalization of traditional Chinese medicine for domestic enterprises. Hua Tuo Rezao Pills have entered the world as a drug, exported to 29 countries and regions including Russia and Vietnam, and entered the Vietnamese national medical insurance drug catalog and obtained a permanent approval for Russian drug registration, successfully entering the international mainstream market for cardiovascular and cerebrovascular disease prevention and treatment drugs.

Recommend Related Products

版权所有 © 宁波全贸信息技术有限公司 浙ICP备12012821号-1 浙B2-20200628

浙公网安备 33020902000078号